04:13 AM EDT, 06/25/2024 (MT Newswires) -- Evotec (EVO) said Tuesday its Seattle-based subsidiary received a multi-year contract of up to $39 million to support the US Department of Defense's effort to enhance its rapid response capabilities for biologics medical countermeasures.

The company said its Just-Evotec Biologics unit was selected to support development of an accelerated monoclonal antibody for the DoD's manufacturing optimization program.

Price: 4.5100, Change: -0.09, Percent Change: -1.96